CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Long-Term Clinical Benefits of a Platelet Glycoprotein 2b/3a Receptor Blocker, Abciximab ReoProR, in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention
Doo Sun Sim, Myung Ho Jeong, Weon Kim, Jay Young Rhew, Ju Hyup Yum, Ju Han Kim, Jeong Gwan Cho, Young Keun Ahn, Jong Chun Park, Byoung Hee Ahn, Sang Hyung Kim, Jung Chaee Kang
Korean J Intern Med. 2003;18(3):129-137.   Published online 2003 September 1    DOI:

Excel Download

Platelet glycoprotein IIb/IIIa—receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: a review
Clinical Therapeutics. 2001;23(8):1145-1165   Crossref logo
Link1 Link2

The Rescue Use of A Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab; Reo-Pro ) in High-Risk Patients with Acute Myocardial Infarction Underwent Percutaneous Coronary Intervention
Korean Circulation Journal. 2001;31(5):492   Crossref logo
Link1 Link2 Link3

Variability in Extent of Platelet Function Inhibition After Administration of Optimal Dose of Glycoprotein IIb/IIIa Receptor Blockers in Patients Undergoing a High-Risk Percutaneous Coronary Intervention
The American Journal of Cardiology. 2006;97(4):489-493   Crossref logo
Link1 Link2

Abciximab reduces long-term mortality following percutaneous coronary intervention
Evidence-based Cardiovascular Medicine. 2003;7(1):21-23   Crossref logo
Link1 Link2

Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention
Clinical Therapeutics. 2003;25(1):225-234   Crossref logo
Link1 Link2

The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden
Clinical Therapeutics. 2005;27(1):100-110   Crossref logo
Link1 Link2

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial
The Lancet. 2001;357(9272):1915-1924   Crossref logo
Link1 Link2

High-dose tirofiban vs abciximab in acute STEMI patients undergoing primary percutaneous coronary intervention
Cardiovascular Revascularization Medicine. 2009;10(4):264-265   Crossref logo
Link1 Link2

Comparison of abciximab with “high-dose” tirofiban in patients undergoing percutaneous coronary intervention
International Journal of Cardiology. 2006;109(1):16-20   Crossref logo
Link1 Link2

Cardioprotective Effects of Oral Nicorandil Use in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention
Journal of Interventional Cardiology. 2014;27(5):472-481   Crossref logo

This metadata service is kindly provided by CrossRef from May 29, 2014. Korean J Intern Med has participated in CrossRef Text and Data Mining service since August 31, 2015.